| Sa Limberg, Inc | |
|
1315 Arrowhead Dr Arbor Vitae WI 54568-9778 | |
| (715) 356-6146 | |
| (715) 358-9556 |
| Full Name | Sa Limberg, Inc |
|---|---|
| Speciality | Social Worker |
| Location | 1315 Arrowhead Dr, Arbor Vitae, Wisconsin |
| Authorized Official Name and Position | Shirley Limberg (OWNER/OPERATOR) |
| Authorized Official Contact | 7153566146 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sa Limberg, Inc 8618 Hwy 51 N P O Box 86 Minocqua WI 54548-9347 Ph: (715) 356-6146 | Sa Limberg, Inc 1315 Arrowhead Dr Arbor Vitae WI 54568-9778 Ph: (715) 356-6146 |
| NPI Number | 1649725888 |
|---|---|
| Provider Enumeration Date | 08/17/2016 |
| Last Update Date | 11/16/2016 |
| Medicare PECOS PAC ID | 3476832338 |
|---|---|
| Medicare Enrollment ID | O20161116002142 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649725888 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 3396-125 (Wisconsin) | Secondary |
| 104100000X | Social Worker | 2773-123 (Wisconsin) | Primary |
| Provider Name | Shirley A Limberg |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1053432344 PECOS PAC ID: 3375822240 Enrollment ID: I20161116002294 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
| Provider Name | Suzanne L Scheldroup |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1952447310 PECOS PAC ID: 6608155536 Enrollment ID: I20161117001222 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
| Provider Name | Diane Marilyn Baird |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1578698916 PECOS PAC ID: 8426400045 Enrollment ID: I20240119000870 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
| Provider Name | David F. Wiltzius |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1811101421 PECOS PAC ID: 2062865595 Enrollment ID: I20240131002087 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
| Provider Name | Debra Ann Hilgart |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1760518765 PECOS PAC ID: 5496102238 Enrollment ID: I20240219002432 |
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago
News Archive
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
Researchers at Emory University School of Medicine and their colleagues have discovered a genetic mechanism that controls cellular growth in the fruit fly Drosophila melanogaster, and believe it likely that a similar system may be at work in normal and cancerous human cells.
Research to develop more effective treatments for triple negative breast cancer - a difficult disease to cure - could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.
Currently, with a pre-malignant breast cancer diagnosis from a biopsy, there are three options: observation, chemoprevention or surgery, all of which require a patient to make decisions while operating from a place of fear and unknown outcomes.
Under this program, known as the 340 B program, drugmakers provide discounts to community health centers and other health care providers that treat vulnerable populations in exchange for having their drugs covered by Medicaid.
› Verified 1 days ago